ASHKENAZI, AVI,QING, JING,WIESMANN, CHRISTIAN,WU, YAN
申请号：
PE2011001694
公开号：
PE20120553A1
申请日:
2010.03.24
申请国别(地区):
PE
年份:
2012
代理人:
摘要：
It refers to a kind of humanized single clone chemical antibody, which is against the future generations fund, including: (1) hvr-h1, including sec No. 149 sequence, (2) hvr-h2, including sec No. 150 sequence, (3) hvr-h3, including sec No. 151 sequence, (4) hvr-l1, including sec No. 146 sequence. Hvr-l2, including sec No.: 147 and (VI) hvr-l3, including sec No.: 148； heavy chain variable area includes sec No.: 132； light chain variable area includes sec No.: 133. He also mentioned an effective pharmacological synthesis in the treatment of bladder cancerSE REFIERE A UN ANTICUERPO MONOCLONAL QUIMERICO HUMANIZADO QUE ES ANTAGONISTA ANTI-FGFR3 QUE COMPRENDE: i) HVR-H1 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 149, ii) HVR-H2 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 150, iii) HVR-H3 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 151, iv) HVR-L1 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 146, v) HVR-L2 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 147, Y vi) HVR-L3 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 148； EN DONDE LA REGION VARIABLE DE CADENA PESADA COMPRENDE LA SEC ID Nº: 132 Y LA REGION VARIABLE DE CADENA LIGERA COMPRENDE LA SEC ID Nº: 133. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER DE VEJIGA, MIELOMA MULTIPLE
